

Andrea Spagnoletti

ESPERIENZA LAVORATIVA

16/04/2024 - ATTUALE Milano, Italia

DIRIGENTE IN ONCOLOGIA MEDICA, UNITÀ MELANOMI FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI DI MILANO

ISTRUZIONE E FORMAZIONE

01/10/2019 - 31/10/2024 Milano, Italia

SPECIALIZZAZIONE IN ONCOLOGIA MEDICA Università "La Statale" di Milano

01/10/2012 - 24/07/2018 Roma, Italia

LAUREA MAGISTRALE IN MEDICINA E CHIRURGIA Università "La Sapienza" di Roma

COMPETENZE LINGUISTICHE

Lingua madre: ITALIANO

Altre lingue:

	COMPRENSIONE		ESPRESSIONE ORALE		SCRITTURA
	Ascolto	Lettura	Produzione orale	Interazione orale	
INGLESE	C1	C1	C1	C1	C1

Livelli: A1 e A2: Livello elementare B1 e B2: Livello intermedio C1 e C2: Livello avanzato

COMPETENZE DIGITALI

Social Network | Gestione autonoma della posta e-mail | Posta elettronica | Windows

PUBBLICAZIONI

2024

Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review

Scrivi qui la descrizione...

Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review A Prelaj, V Miskovic, M Zanitti, F Trovo, C Genova... - Annals of Oncology, 2024

Link https://www.sciencedirect.com/science/article/pii/S0923753423043314

2021

Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy

Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy G Fucà, A Spagnoletti, M Ambrosini, F De Braud... - ESMO open, 2021

Link https://www.sciencedirect.com/science/article/pii/S2059702920329124

2022

Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors

Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors R Lobefaro, S Rota, L Porcu, C Brunelli, S Alfieri, E Zito... - ESMO open, 2022

Link https://www.sciencedirect.com/science/article/pii/S2059702922000746

2023

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients A Prelai, EG Galli, V Miskovic, M Pesenti, G Viscardi... - Frontiers in Oncology, 2023

Link https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1078822/full

2023

1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group

1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: a collaborative work from ESMO real-world data and Digital Health Working Group A Pellat - Annals of Oncology, 2023

Link https://www.annalsofoncology.org/article/S0923-7534(23)03480-4/fulltext

2023

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1< 50%: a multiomics analysis

Scrivi qui la descrizione...

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1< 50%: a multiomics analysis GL Russo, A Prelaj, - Journal for Immunotherapy of Cancer, 2023

Link https://pmc.ncbi.nlm.nih.gov/articles/PMC10254948/

2022

Prognostic and predictive role of body mass Index (BMI) in metastatic colorectal cancer (mCRC): a pooled analisys of tribe and tribe-2 studies by GONO

Prognostic and predictive role of body mass Index (BMI) in metastatic colorectal cancer (mCRC): a pooled analisys of tribe and tribe-2 studies by GONO E Dell'Aquila, D Rossini, A Galletti, M Stellato... - Clinical Colorectal Cancer, 2022

Link https://www.sciencedirect.com/science/article/abs/pii/S153300282200024X

2024

Apollo 11 project, consortium in advanced lung cancer patients treated with innovative therapies: Integration of real-world data and translational research

Apollo 11 project, consortium in advanced lung cancer patients treated with innovative therapies: Integration of real-world data and translational research A Prelaj, M Ganzinelli, L Provenzano, L Mazzeo... - Clinical Lung Cancer, 2024

Link https://www.sciencedirect.com/science/article/abs/pii/S1525730423002693

2024

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma RS Goodman, L Di Guardo, A Maurichi, B Kirwin... - European Journal of Cancer, 2023

Link https://www.sciencedirect.com/science/article/abs/pii/S0959804923006561

2022

Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease

Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease A Spagnoletti, M Platania, M Brambilla, M Occhipinti... - Tumori Journal, 2022

Link https://journals.sagepub.com/doi/full/10.1177/03008916211067565

2022

Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials

Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials E Dell'Aquila - ESMO open, 2022

Link https://www.sciencedirect.com/science/article/pii/S2059702922002368

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review SB Urtecho, L Provenzano, A Spagnoletti, A Bottiglieri... - Lung Cancer, 2024

Link https://www.lungcancerjournal.info/article/S0169-5002(24)00585-3/fulltext

2023

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer patients treated with upfront chemotherapy plus Bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer patients treated with upfront chemotherapy plus Bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies V Fanotto - Cancers, 2023

Link https://www.mdpi.com/2072-6694/15/22/5451

2022

Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center G Fucà - Therapeutic Advances in Medical Oncology, 2022

Link https://journals.sagepub.com/doi/full/10.1177/17588359221108687

2021

Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma

Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma L Provenzano, V Cuccarini, M Platania, L Canziani... - Tumori Journal, 2021

Link https://journals.sagepub.com/doi/full/10.1177/03008916211052330

2020

Metastatic sarcoma: tailored strategies for a heterogeneous disease

Metastatic sarcoma: tailored strategies for a heterogeneous disease M Grassi, A Spagnoletti, A Puccini - memo-Magazine of European Medical Oncology, 2020

Link https://link.springer.com/article/10.1007/s12254-020-00598-w

Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records

Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records L Mazzeo, F Corso, P Baili, F Scotti, V Torri... - ESMO Real World Data and Digital Oncology, 2025

Link https://www.sciencedirect.com/science/article/pii/S2949820124000870

Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours

Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours A Pellat - ESMO Real World Data and Digital Oncology, 2024

Link https://www.sciencedirect.com/science/article/pii/S2949820124000699

2024

Integrating radiomics and real-world data to predict immune-checkpoint inhibitors efficacy in advanced Non-Small Cell Lung Cancer

Integrating radiomics and real-world data to predict immune-checkpoint inhibitors efficacy in advanced Non-Small Cell Lung Cancer L Provenzano, M Favali, L Mazzeo, A Spagnoletti... - 2024

Link https://www.researchsguare.com/article/rs-4763917/v1

2024

1320P Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy

1320P Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy A Prelaj, M Sacco, V Miskovic, D Lorenzini, F Trovò... - Annals of Oncology, 2024

Link https://www.annalsofoncology.org/article/S0923-7534(24)02895-3/fulltext

2023

178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients

178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients L Provenzano, M Favali, L Mazzeo, A Spagnoletti... - Annals of Oncology, 2023

Link https://www.annalsofoncology.org/article/S0923-7534(23)03739-0/fulltext

2023

TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients

TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients B Borelli, S Crucitta, A Boccaccino, M Antista... - Tumori Journal, 2023

Link <u>https://journals.sagepub.com/doi/full/10.1177/03008916221147944</u>

2023

68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC

68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC P Ambrosini, L Provenzano, A Bottiglieri, A Spagnoletti... - Journal of Thoracic Oncology, 2023

Link https://www.jto.org/article/S1556-0864(23)00322-2/pdf

2022

72P Treatments response in non-small cell lung cancer patients according to BRCA status on liquid biopsy: A retrospective analysis

72P Treatments response in non-small cell lung cancer patients according to BRCA status on liquid biopsy: A retrospective analysis L Provenzano, A Bottiglieri, A Spagnoletti, G Di Guida... - Immuno-Oncology and Technology, 2022

Link https://www.esmoiotech.org/article/S2590-0188(22)00107-1/fulltext

2022

1071P Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients

1071P Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in et al. non-small cell lung cancer patients A Prelaj - Annals of Oncology, 2022

Link https://www.annalsofoncology.org/article/S0923-7534(22)03048-4/fulltext

2022

1056P KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC

1056P KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC A Bottiglieri, L Provenzano, A Spagnoletti, L Mazzeo... - Annals of Oncology, 2022

Link https://www.annalsofoncology.org/article/S0923-7534(22)03033-2/fulltext

2022

413P Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT)+ bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies

413P Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT)+ bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies V Fanotto et al. - Annals of Oncology, 2022

Link https://www.annalsofoncology.org/article/S0923-7534(22)02402-4/pdf

2022

Negative ultra-selection of patients with RAS/BRAF wild-type (wt), microsatellite stable (MSS) metastatic colorectal cancer (mCRC) receiving anti-EGFR-based therapy: The PRESSING2 study

Negative ultra-selection of patients with RAS/BRAF wild-type (wt), microsatellite stable (MSS) metastatic colorectal cancer (mCRC) receiving anti-EGFR-based therapy: The PRESSING2 study G Randon et al. - Cancer Research, 2022

Link https://aacrjournals.org/cancerres/article/82/12 Supplement/1269/702994

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali".